



## **ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023**

February 9, 2023

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported that Richard Lowenthal, M.Sc., MSEL, co-founder and chief executive officer, and Eric Karas, chief commercial officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference 2023 on Thursday, February 16, 2023 at 2:20 p.m. ET.

A live webcast will be available in the investor section of the company's website at [www.ars-pharma.com](http://www.ars-pharma.com). The webcast will be archived for 30 days following the presentation.

### **About ARS Pharmaceuticals, Inc.**

ARS is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing *neffy*<sup>®</sup> (previously referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit [www.ars-pharma.com](http://www.ars-pharma.com).

### **ARS Investor Contact:**

Justin Chakma  
ARS Pharmaceuticals  
[justinc@ars-pharma.com](mailto:justinc@ars-pharma.com)

ARS Pharmaceuticals, Inc.